Differentiation of smooth muscle progenitor cells in peripheral blood and its application in tissue engineered blood vessels
Authors:
- 4 December 2008
- journal article
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 9 (12) , 923-930
Abstract
A major shortcoming in tissue engineered blood vessels (TEBVs) is the lack of healthy and easily attainable smooth muscle cells (SMCs). Smooth muscle progenitor cells (SPCs), especially from peripheral blood, may offer an alternative cell source for tissue engineering involving a less invasive harvesting technique. SPCs were isolated from 5-ml fresh rat peripheral blood by density-gradient centrifugation and cultured for 3 weeks in endothelial growth medium-2-MV (EGM-2-MV) medium containing platelet-derived growth factor-BB (PDGF BB). Before seeded on the synthesized scaffold, SPC-derived smooth muscle outgrowth cell (SOC) phenotypes were assessed by immuno-fluorescent staining, Western blot analysis, and reverse transcription polymerase chain reaction (RT-PCR). The cells were seeded onto the silk fibroin-modified poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (SF-PHBHH x ) scaffolds by 6×104 cells/cm2 and cultured under the static condition for 3 weeks. The growth and proliferation of the seeded cells on the scaffold were analyzed by 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT) assay, scanning electron microscope (SEM), and 4,6-diamidino-2-phenylindole (DAPI) staining. SOCs displayed specific “hill and valley” morphology, expressed the specific markers of the SMC lineage: smooth muscle (SM) α-actin, calponin and smooth muscle myosin heavy chain (SM MHC) at protein and messenger ribonucleic acid (mRNA) levels. RT-PCR results demonstrate that SOCs also expressed smooth muscle protein 22α (SM22α), a contractile protein, and extracellular matrix components elastin and matrix Gla protein (MGP), as well as vascular endothelial growth factor (VEGF). After seeded on the SF-PHBHH x scaffold, the cells showed excellent metabolic activity and proliferation. SPCs isolated from peripheral blood can be differentiated into the SMCs in vitro and have an impressive growth potential in the biodegradable synthesized scaffold. Thus, SPCs may be a promising cell source for constructing TEBVs.Keywords
This publication has 30 references indexed in Scilit:
- In vitro evaluation of electrospun silk fibroin scaffolds for vascular cell growthBiomaterials, 2008
- Co‐expression of elastin and collagen leads to highly compliant engineered blood vesselsJournal of Biomedical Materials Research Part A, 2008
- Contractile smooth muscle cells derived from hair-follicle stem cellsCardiovascular Research, 2008
- Progenitor cells and vascular diseaseCell Proliferation, 2007
- Functional tissue-engineered blood vessels from bone marrow progenitor cellsCardiovascular Research, 2007
- In vivo vasculogenic potential of human blood-derived endothelial progenitor cellsBlood, 2007
- Mechanical Properties and Compositions of Tissue Engineered and Native ArteriesAnnals of Biomedical Engineering, 2007
- Cellular therapy and myocardial tissue engineering: the role of adult stem and progenitor cellsEuropean Journal of Cardio-Thoracic Surgery, 2006
- Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cellsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Molecular Regulation of Vascular Smooth Muscle Cell Differentiation in Development and DiseasePhysiological Reviews, 2004